Publication Year

Kerger BD, Tvermoes BE, Unice KM, Finley BL, Paustenbach DJ, Galbraith DA. 2013. Cobalt speciation assay for human serum, Part II. Method validation in a study of human volunteers ingesting cobalt (II) chloride dietary supplement for 90 days. Toxicol Environ Chem 95(4):709–718; doi: 10.1080/02772248.2013.792559.

Kerger BD, Gerads R, Gurleyuk H, Thuett KA, Finley BL, Paustenbach DJ. 2013. Cobalt speciation assay for human serum, Part I. Method for measuring large and small molecular cobalt and protein-binding capacity using size exclusion chromatography with inductively-coupled plasma-mass spectroscopy detection. Toxicol Environ Chem 95(4):687–708; doi: 10.1080/02772248.2013.793444.

Finley BL, Unice KM, Kerger BD, Otani JM, Paustenbach DJ, Galbraith DA, Tvermoes BE. 2013. 31-day study of cobalt (II) chloride ingestion in humans: Pharmacokinetics and clinical effects. J Toxicol Environ Health A, 76:1210–1224; doi: 10.1080/15287394.2013.848391. PMID: 24283372.

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell, ME. 2013. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 28(7):876–885.

Urban JD, Carakostas MC, Brusick, DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51:386-390.

Thompson CM, Kirman CR, Proctor DM, Suh M, Hays SM, Haws LC, Harris MA. 2013. A chronic oral reference dose for hexavalent chromium. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Racz L, Baker PA, Duckworth KL, Heline TR, Woodall BD. 2013. Environmental planning while deployed: Mission hindrance or enhancement? Joint Force Quarterly 70:30–33.

Flory J, Kanel SR, Racz L, Impellitteri CA, Rendahandi GS, Goltz MN. 2013. Influence of pH on the transport of silver nanoparticles in saturated porous media: laboratory experiments and modeling. J Nanopart Res 15(3):2–11.

Fryzek J, Pastula S, Jiang X, Garabrant DH. 2013. Childhood cancer incidence in Pennsylvania counties in relation to living in counties with hydraulic fracturing sites. J Occup Environ Med 55(7):796–801.

Fryzek J, Pastula S, Jiang X, Garabrant DH. 2013. Response to Goldstein et al. J Occup Environ Med 55(11):1378.

Liu L, Aguirre SA, Hosea NA, Scott W, May JR, Burns-Naas LA, et al. 2014. Intermittent oral coadministration of a gamma secretase inhibitor with dexamethasone mitigates intestinal goblet cell hyperplasia in rats. Toxicol Pathol 42(2):422–434.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. 2013. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at the Society of Toxicology Annual Meeting, San Antonio, TX, March 2013.

Patterson J, Maier A, Kohrman-Vincent M, Dourson ML. 2013. Peer consultation on relationship between PAC profile and toxicity of petroleum substances. Regul Toxicol Pharmacol 67:S86–S93.

Belova A, Narayan T, Brown L, Haskell J, Bozeman S, Lamb J. A framework to assess aflatoxin public health impacts in developing countries with application to Nigeria and Tanzania. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Brown L, Lynch M, Post E, Belova A. Determine a concentration response relationship suitable for estimating adult benefits of reduced lead exposure. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Karchapati L, Bednar KJ, Adams DE, Wu Y, Mitter RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. 2013. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 47:94–103.